Nuclear Medicine and Biology
Volume 36, Issue 4 , Pages 345-354 , May 2009

Melanoma imaging using 111In-, 86Y- and 68Ga-labeled CHX-A″-Re(Arg11)CCMSH

  • Lihui Wei

      Affiliations

    • Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
    • Current affiliation: MDS Nordion, Ottawa, ON, Canada K2K 1X8.
    • ,
  • Xiuli Zhang

      Affiliations

    • Department of Biochemistry, University of Missouri-Columbia, Columbia, MO 65211, USA
    • Harry S. Truman Veterans Administration Hospital, Columbia, MO 65201, USA
    • ,
  • Fabio Gallazzi

      Affiliations

    • Department of Biochemistry, University of Missouri-Columbia, Columbia, MO 65211, USA
    • ,
  • Yubin Miao

      Affiliations

    • Department of Biochemistry, University of Missouri-Columbia, Columbia, MO 65211, USA
    • Harry S. Truman Veterans Administration Hospital, Columbia, MO 65201, USA
    • Current affiliation: College of Pharmacy, University of New Mexico, Albuquerque, NM 87131, USA.
    • ,
  • Xiaofang Jin

      Affiliations

    • Department of Biochemistry, University of Missouri-Columbia, Columbia, MO 65211, USA
    • ,
  • Martin W. Brechbiel

      Affiliations

    • Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, Bethesda, MD 20893, USA
    • ,
  • Heng Xu

      Affiliations

    • Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, Bethesda, MD 20893, USA
    • ,
  • Thomas Clifford

      Affiliations

    • Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, Bethesda, MD 20893, USA
    • ,
  • Michael J. Welch

      Affiliations

    • Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
    • ,
  • Jason S. Lewis

      Affiliations

    • Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
    • Current affiliation: Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
    • ,
  • Thomas P. Quinn

      Affiliations

    • Department of Biochemistry, University of Missouri-Columbia, Columbia, MO 65211, USA
    • Harry S. Truman Veterans Administration Hospital, Columbia, MO 65201, USA
    • Corresponding Author InformationCorresponding author. Department of Biochemistry, University of Missouri, Columbia, MO 65211, USA. Tel.: +1 573 882 6099; fax: +1 573 882 5635.

Received 19 November 2008 ,Revised 15 December 2008 ,Accepted 5 January 2009.

References 

  1. Giblin MF, Wang N, Hoffman TJ, Jurisson SS, Quinn TP. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc of the Natl Acad Sci U S A. 1998;95:12814–12818
  2. Vaidyanathan G, Zalutsky MR. Fluorine-18-labeled [Nle4,d-Phe7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue. Nucl Med Biol. 1997;24:171–178
  3. Chen JQ, Cheng Z, Hoffman TJ, Jurisson SS, Quinn TP. Melanoma-targeting properties of 99mttechnetium-labeled cyclic α-melanocyte stimulating hormone peptide analogues. Cancer Res. 2000;60:5649–5658
  4. Chen JQ, Cheng Z, Owen NK, Hoffman TJ, Miao Y, Jurisson SS, et al. Evaluation of an 111In-DOTA-rhenium cyclized α-MSH analog: a novel cyclic-peptide analog with improved tumor targeting properties. J Nucl Med. 2001;42:1847–1855
  5. Froidevaux S, Calame-Christe M, Tanner H, Sumanovski L, Eberle AN. A novel DOTA-α-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med. 2002;43:1699–1706
  6. Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M, et al. A gallium-labeled DOTA-alpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med. 2004;45:116–123
  7. McQuade P, Miao Y, Yoo J, Quinn TP, Welch MJ, Lewis JS. Imaging of melanoma using 64Cu- and 86Y- DOA-ReCCMSH(Arg11), a cyclic peptide analogue of α-MSH. J Med Chem. 2005;48:2985–2992
  8. Wei L, Butcher C, Miao Y, Gallazzi F, Quinn TP, Welch MJ, et al. Synthesis and biological evaluation of 64Cu-labled rhenium-cyclized α-MSH peptide analogs using a cross-bridged cyclam chelator. J Nucl Med. 2007;48:64–72
  9. Wei L, Miao Y, Gallazzi F, Quinn TP, Welch MJ, Vavere AL, et al. Ga-68 Labeled DOTA-rhenium cyclized α-MSH analog for imaging of malignant melanoma. Nucl Med Biol. 2007;34:945–953
  10. Cheng Z, Xiong Z, Subbarayan M, Chen X, Gambhir SS. 64Cu-Labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem. 2007;18:765–772
  11. Cheng Z, Zhang L, Graves E, Xiong Z, Dandekar M, Chen X, et al. Small-animal PET of melanocortin-1 receptor expression using a 18F-labeled α-melanocyte stimulating hormone analog. J Nucl Med. 2007;48:987–994
  12. Miao Y, Owen NK, Darrell R, Fisher DR, Hoffman TJ, Quinn TP. Therapeutic efficacy of a 188Re labeled α-melanocyte stimulating hormone peptide analogue in murine and human melanoma-bearing mouse models. J Nucl Med. 2005;46:121–129
  13. Miao Y, Hylarides M, Fisher DR, Shelton T, Moore H, et al. Melanoma therapy via peptide-targeted alpha-radiation. Clin Cancer Res. 2005;11:5616–5621
  14. Miao Y, Shelton T, Quinn TP. Therapeutic efficacy of a 177Lu labeled DOTA conjugated α-melanocyte stimulating hormone peptide in a murine melanoma-bearing mouse model. Cancer Biother Radiopharm. 2007;22:333–341
  15. Bard DR, Knight CG, Page-Thomas DP. A chelating derivative of α-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma. Br J Cancer. 1990;62:919–922
  16. Wraight EP, Bard DR, Maughan TS, Knight CG, Page-Thomas DP. The use of a chelating derivative of alpha melanocytes stimulating hormone for the clinical diagnosis of malignant melanoma. Br J Radiol. 1992;65:112–118
  17. Hruby VJ, Cai M, Grieco P, Han G, Kavarana M, Trivedi D. Exploring the stereostructural requirements of peptide ligands for the melanocortin receptors. Ann N Y Acad Sci. 2003;994:12–20
  18. Schioth HB, Haitina T, Ling MK, Ringholm A, Fredriksson R, Cerda-Reverter JM, et al. Evolutionary conservation of the structural, pharmacological and genomic characteristics of melanocortin receptor subtypes. Peptides. 2005;26:1886–1900
  19. Roberts DW, Newton RA, Beaumont KA, Leonard JH, Strum RA. Quantitative analysis of MC1R gene expression in human skin cell cultures. Pigment Cell Res. 2005;19:76–89
  20. Siegrist W, Solca F, Stutz S, Giuffre L, Carrel S, Girard J, et al. Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Res. 1989;49:6352–6358
  21. Tatro JB, Atkins M, Mier JW, Hardarson S, Wolfe H, Smith T, et al. Melanotropin receptors demonstrated in situ in human melanoma. J Clin Invest. 1990;85:1825–1832
  22. Miao Y, Whitener D, Feng W, Owen NK, Chen JQ, Quinn TP. Evaluation of the human melanoma targeting properties of radiolabeled α-melanocyte stimulating hormone peptide analogues. Bioconjug Chem. 2003;14:1177–1184
  23. Schubiger PA, Alberto R, Smith A. Vehicles, chelators and radionuclides: choosing the “building blocks” of an effective therapeutic radioimmunoconjugate. Bioconjug Chem. 1996;7:165–179
  24. Cheng Z, Chen J, Owen N, Miao Y, Quinn TP, Jurisson SS. Modification of the structure of a metallopeptide: synthesis and biological evaluation of 111In labeled DOTA conjugated rhenium cyclized α-MSH analogs. J Med Chem. 2002;45:3048–3056
  25. Miao Y, Benwell K, Quinn TP. 99mTc and 111In-labeled α-melanocyte stimulation hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J Nucl Med. 2007;48:73–80
  26. Miao Y, Hoffman TJ, Quinn TP. Tumor targeting properties of 90Y and 177Lu labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nucl Med Biol. 2005;32:485–493
  27. Brechbiel MW, Gansow OA, Pippen CG, Rogers RD, Planalp RP. Preparation of the novel chelating agent N-(2-aminoethyl)-trans-1,2-diaminocyclohexane N,N′,N′′-pentaacetic acid (H5CyDTPA), a preorganized analogue of diethylenetriaminepentaacetic acid (H5DTPA), and the structures of BiIII(CyDTPA)2- and BiIII(H2DTPA) complexes. Inorg Chem. 1996;35:6343–6348
  28. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma DS, Abdulla A, et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res. 2004;10:7834–7841
  29. Huneke RB, Pippin CG, Squire RA, Brechbiel MW, Gansow OA, Strand M. Effective α-particle-mediated radioimmunotherapy of murine leukemia. Cancer Res. 1992;52:5818–5820
  30. Lee FT, Mountain AJ, Kelly MP, Hall C, Rigopoulos A, Johns TG, et al. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A′′-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. Clin Cancer Res. 2005;11:7080–7086
  31. Blend MJ, Stastny JJ, Swanson SM, Brechbiel MW. Labeling anti-HER2/neu monoclonal antibodies with 111In and 90Y using a bifunctional DTPA chelating agent. Cancer Biother Radiopharm. 2003;18:355–363
  32. Milenic DE, Garmestani K, Chappell LL, Dadachova E, Yordanov A, Ma D, et al. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl Med Biol. 2002;29:431–442
  33. Clifford T, Boswell CA, Biddlecombe GB, Lewis JS, Brechbiel MW. Validation of a novel CHX-A′′ derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A′′-Octreotide. J Med Chem. 2007;49:4297–4304
  34. Yoo J, Tang L, Perkins TA, Rowland DJ, Laforest R, Lewis JS, et al. Preparation of high specific activity 86Y using a small biomedical cyclotron. Nuc Med Biol. 2005;32:891–897
  35. Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MN, Heward CE, Burnett JB, et al. [Nle4,d-Phe7] α-Melanocyte stimulating hormone: a highly potent α-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980;77:5754–5758
  36. Stimmel JB, Stockstill ME, Kull FC. Yttrium-90 chelation properties of tetraazatetraacetic acid macrocycles, diethylenetriaminepenataacetic acid analogues, and a novel terpyridine acyclic chelator. Bioconjug Chem. 1995;6:219–225
  37. Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev. 2004;56:1–29
  38. Miao Y, Figueroa SD, Fisher DR, Moore HA, Testa RF, Hoffman TJ, et al. 203Pb-Labeled α-melanocyte stimulating hormone peptide as an imaging probe for melanoma detection. J Nucl Med. 2008;49:823–829
  39. Bernard BF, Krenning EP, Breeman WAP, Rolleman EJ, Bakker WH, Visser TJ, et al. d-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med. 1997;38:1929–1933
  40. Eckelman WC, Volkert WA, Bonardi M. True radiotracers: are we approaching the theoretical specific activity with Tc-99m and I-123?. Nucl Med Biol. 2008;35:523–527

☆ The authors would like to acknowledge support from the National Cancer Institute P50-103130, R24 CA86307, the NIH Clinical Biodetective Graduate Training Grant R90DK071510 and the Harry S. Truman Veterans Administration Hospital Biomolecular Imaging Center, Columbia, MO, USA. Small animal PET imaging was supported by an NIH/NCI SAIRP grant (R24 CA86060) with additional support from the Small Animal Imaging Core of the Alvin J. Siteman Cancer Center at Washington University and Barnes-Jewish Hospital. The SAIC is supported by an NCI Cancer Center Support Grant P30 CA91842. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

PII: S0969-8051(09)00007-9

doi: 10.1016/j.nucmedbio.2009.01.007

Nuclear Medicine and Biology
Volume 36, Issue 4 , Pages 345-354 , May 2009

Article Tools

* Image Usage & Resolution